Farnesyltransferase inhibitors: promises and realities.
Farnesyltransferase inhibitors have recently shown clinical efficacy against leukemias, gliomas and even non-small-cell lung cancers, especially when administered in combination with taxanes. It is possible that the critical target downstream of farnesyltransferase responsible for these effects is not either Ras or RhoB, the two most cited possibilities - but the hunt is on.
Department of Radiation Oncology CB #7512, 1050 Gravely Building, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7512, USA. cox@radonc.unc.edu
Adrienne D
AD
Cox
Channing J
CJ
Der
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D051231:Farnesyltranstransferase; D011905:Genes, ras / Q000187:drug effects / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology
D004791:Enzyme Inhibitors; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase